Hansen Medical®, Inc., the global leader in intravascular robotics, today announced the completion of an exclusive distribution agreement for commercial activities for the Magellan™ Robotic System in China.
The agreement is with China National Medical Device Co., Ltd. (CMIC), a subsidiary of CSMIC (China National Scientific Instruments and Materials Corp.), which reports into SINOPHARM, China's largest Pharmaceutical and Healthcare group. China National Medical Device Co., Ltd. (CMIC) reported approximately $1.3 billion in 2013 revenue, has over 1900 employees and boasts the largest nationwide medical device sales network, covering more than 20 provinces in China. As part of the distribution agreement, China National Medical Device Co., Ltd. (CMIC) is responsible for obtaining all regulatory approvals from the Chinese agencies. Further, the distribution agreement with Hansen Medical calls for an initial purchasing commitment for Magellan Robotic Systems.
"We are very excited to be partnering with Hansen Medical in the field of Intravascular Robotics," said Dr. Yingzhi Wang, General Manager of China National Medical Device Co., Ltd. (CMIC). "Vascular disease is quite prevalent in China and we anticipate that the Magellan Robotic System will become a key technology for physicians treating an expanding patient population seeking endovascular therapies."
"The entire team at Hansen Medical is excited about our partnership with China National Medical Device Co., Ltd. (CMIC)," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "Further, we are enthusiastic about the significant opportunities in China as we build on our strategy to expand commercialization efforts for the Magellan Robotic System in Asia."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe. The Magellan Robotic System offers several important features including:
- Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
- Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line
- Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
- Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
- The Magellan 9Fr Robotic Catheter allows for independent, robotic control of the distal tip of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
- The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
Source: http://www.hansenmedical.com/